Results 41 to 50 of about 23,616 (164)

Identification of protein interaction antagonists using the repressed transactivator two-hybrid system

BioTechniques, 2007
The repressed transactivator (RTA) yeast two-hybrid system was developed to enable genetic identification of interactions with transcriptional activator proteins.
Phalgun B. Joshi, Martin Hirst, Tom Malcolm, Jennifer Parent, David Mitchell, Karen Lund, Ivan Sadowski   +6 more
doaj   +1 more source

Nano-Emulsion Incorporating Squalene and Mn2+ Stabilized by TA/Mn2+ Networks Enhances Subunit Vaccine Immunogenicity

International Journal of Nanomedicine
Kai Chen,1 Linlin Li,1 Ning Wang,1 Yunfeng Deng,1 Chuanying Xiang,1 Xiaomin Zhang,1 Yangyang Zhou,1 Hong Yang,1 Yu Xie,1 Xiaoting Chen,2 Ying Li,3 Yan Li,1 Gang Guo,1 Yun Shi1 1Institute of Biopharmaceuticals, West China Hospital, Sichuan University ...
Chen K, Li L, Wang N, Deng Y, Xiang C, Zhang X, Zhou Y, Yang H, Xie Y, Chen X, Li Y, Li Y, Guo G, Shi Y   +13 more
doaj  

Microbial Genome Editing with CRISPR–Cas9: Recent Advances and Emerging Applications Across Sectors

Fermentation
CRISPR technology, which is derived from the bacterial adaptive immune system, has transformed traditional genetic engineering techniques, made strain engineering significantly easier, and become a very versatile genome editing system that allows for ...
Chhavi Dudeja, Amish Mishra, Ansha Ali, Prem Pratap Singh, Atul Kumar Jaiswal   +4 more
doaj   +1 more source

Compliant immune response of silk-based biomaterials broadens application in wound treatment

Frontiers in Pharmacology
The unique properties of sericin and silk fibroin (SF) favor their widespread application in biopharmaceuticals, particularly in wound treatment and bone repair.
Zhiqiang Tian, Hong Chen, Ping Zhao
doaj   +1 more source

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases

Clinical Pharmacology: Advances and Applications, 2017
Erwin Dreesen,1 Peter Bossuyt,2,3 Denis Mulleman,4 Ann Gils,1 Dora Pascual-Salcedo5 1Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, 2Imelda GI Clinical Research Centre ...
Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D   +4 more
doaj  

Biopharmaceutical Innovation System and the Influence of Policies: The Case of Taiwan (2000-2008) [PDF]

International Journal of Health Policy and Management, 2013
This article discusses the influence of policies on the development of biopharmaceuticals. We choose the experiences of Taiwan for our empirical study and focus on the evolution between 2000 and 2008; in the period of time the country provides an ...
Chao Chen Chung
doaj  

АДАПТАЦИОННЫЕ ОСОБЕННОСТИ МУРАВЬЕВ FORMICA RUFA LINNAEUS В РАЗНЫХ КЛИМАТИЧЕСКИХ ЗОНАХ

Cifra: Биологические науки
В работе обоснован значительный медицинский и биотехнологический потенциал муравьев, обитающих на территории Хабаровского края. Данные насекомые представляют интерес для современной фармацевтики благодаря уникальному биохимическому составу ...
Березовская Л.А., Коновальцева К.А., Кольцов К.И., Млынар Е.В.   +3 more
doaj   +1 more source

Yeasts as Biopharmaceutical Production Platforms

Frontiers in Fungal Biology, 2021
Natalja Kulagina, Sébastien Besseau, Charlotte Godon, Gustavo H. Goldman, Nicolas Papon, Vincent Courdavault   +5 more
doaj   +1 more source

PI3Kγδ inhibition suppresses key disease features in a rat model of asthma

Respiratory Research
Background Two isoforms of Phosphoinositide 3-kinase (PI3K), p110γ and p110δ, are predominantly expressed in leukocytes and represent attractive therapeutic targets for the treatment of allergic asthma.
James W. Pinkerton, Silvia Preite, Antonio Piras, Dimitrios Zervas, Thomais Markou, Mark S. Freeman, Tobias Hofving, Emil Ivarsson, Sara J. Bonvini, Wayne Brailsford, Linda Yrlid, Maria G. Belvisi, Mark A. Birrell   +12 more
doaj   +1 more source

Novel nanobody-161 binds tumor necrosis factor receptor 2 (TNFR2) to exert an anti-tumor effect but does not block TNFα-binding

Frontiers in Immunology
BackgroundTumor necrosis factor receptor 2 (TNFR2) is expressed on regulatory T cells (Tregs) and many cancer cells indicating its potential as a therapeutic target.
Liang Huang, Chao Kong, Chao Kong, Yuhao Hu, Michael Zhang, Shuangqi Li, Wanjing Wang, Hui Guan, Mei Ling Lim, Zhen Zhang, Wenhai Zhang, Hailiang Zheng, Xintian Yan, Xinglu Sun, Pan Lei, Shanshan Dai, Wenrong Wang, Linlin Lu, Junma Zhou, Shilong Fan, Guojun Lang   +20 more
doaj   +1 more source